Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 21
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,929
+25.77%
|
-
|
|
Jan 21
2025
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
42,762
+22.38%
|
-
|
|
Jan 21
2025
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+28.26%
|
-
|
|
Jan 21
2025
|
Nur Nicholson Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,426
+29.17%
|
-
|
|
Jan 21
2025
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,045
+1.29%
|
-
|
|
Jan 21
2025
|
Cedric Francois Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,662
+23.22%
|
-
|
|
Jan 21
2025
|
Caroline Baumal Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,594
+29.79%
|
-
|
|
Jan 21
2025
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,591
+20.37%
|
-
|
|
Jan 21
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,508
+24.88%
|
-
|
|
Jan 17
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,730
-1.96%
|
$50,170
$29.96 P/Share
|
|
Jan 17
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,201
-2.44%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
2,201
-2.04%
|
$63,829
$29.96 P/Share
|
|
Jan 17
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,241
-2.75%
|
$35,989
$29.96 P/Share
|
|
Jan 17
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,145
-3.96%
|
$62,205
$29.96 P/Share
|
|
Jan 17
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
750
-0.07%
|
$21,750
$29.96 P/Share
|
|
Jan 17
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,007
-1.95%
|
$174,203
$29.96 P/Share
|
|
Jan 17
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,853
-3.34%
|
$53,737
$29.96 P/Share
|
|
Jan 17
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
715
-1.91%
|
$20,735
$29.96 P/Share
|
|
Jan 17
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,235
-2.1%
|
$35,815
$29.96 P/Share
|
|
Jan 13
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
4,965
-4.4%
|
$139,020
$28.7 P/Share
|
|
Jan 13
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,170
-2.4%
|
$60,760
$28.7 P/Share
|
|
Jan 13
2025
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,685
-2.89%
|
$75,180
$28.7 P/Share
|
|
Jan 13
2025
|
Karen Lewis Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,599
-3.42%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,632
-4.63%
|
$73,696
$28.7 P/Share
|
|
Jan 13
2025
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
264
-0.46%
|
$7,392
$28.7 P/Share
|
|
Jan 13
2025
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,247
-1.99%
|
$174,916
$28.7 P/Share
|
|
Jan 13
2025
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,599
-2.65%
|
$44,772
$28.7 P/Share
|
|
Jan 13
2025
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,288
-0.2%
|
$64,064
$28.7 P/Share
|
|
Jan 13
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
783
-2.05%
|
$21,924
$28.7 P/Share
|
|
Jan 08
2025
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,090
+50.0%
|
-
|
|
Jan 06
2025
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,816
-4.82%
|
$92,928
$33.81 P/Share
|
|
Jan 01
2025
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+26.14%
|
-
|
|
Jan 01
2025
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+1.64%
|
-
|
|
Jan 01
2025
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+3.81%
|
-
|
|
Jan 01
2025
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+21.63%
|
-
|
|
Jan 01
2025
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,267
+26.14%
|
-
|
|
Dec 31
2024
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,096
+5.65%
|
$155,344
$14.4 P/Share
|
|
Dec 23
2024
|
Jeffrey Eisele Chief Development Officer |
SELL
Open market or private sale
|
Direct |
63
-0.11%
|
$2,079
$33.09 P/Share
|
|
Dec 11
2024
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.25%
|
$170,000
$34.23 P/Share
|
|
Nov 01
2024
|
Cedric Francois Chief Executive Officer |
SELL
Other acquisition or disposition
|
Indirect |
182,146
-27.84%
|
-
|
|
Sep 27
2024
|
David O. Watson General Counsel |
BUY
Bona fide gift
|
Direct |
10,569
+8.24%
|
-
|
|
Sep 27
2024
|
David O. Watson General Counsel |
SELL
Bona fide gift
|
Indirect |
10,569
-13.1%
|
-
|
|
Sep 23
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+2.94%
|
$59,800
$13.19 P/Share
|
|
Sep 16
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
37,000
-14.26%
|
$1,332,000
$36.44 P/Share
|
|
Sep 16
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
192
-0.5%
|
$6,912
$36.21 P/Share
|
|
Sep 03
2024
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
550
-1.41%
|
$21,450
$39.49 P/Share
|
|
Aug 12
2024
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,201
+7.93%
|
$67,613
$13.85 P/Share
|
|
Jun 28
2024
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+0.67%
|
$11,700
$13.19 P/Share
|
|
Jun 21
2024
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
37,000
-10.76%
|
$1,443,000
$39.43 P/Share
|
|
May 20
2024
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,500
+2.1%
|
$73,500
$3.76 P/Share
|